← Leaderboards
Cesar Augusto Santa-Maria
Johns Hopkins University
$1,330,670
Attributed
$1,330,670
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $266.5K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,330,670 · 1
By mechanism
K08$1,330,670 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Elizabeth Marion Jaffee$29,780,612
- Drew M. Pardoll$27,059,898
- Elana Fertig$10,275,542
- Frederick L Brancati$22,508,444
- Young J. Kim$4,039,490
Others in their field
Other Emerging Leaders on “Combination Immunotherapy”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$39,889,328
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108
- Barbara Burtness · Yale University$11,871,804
- Wilton B Williams · Duke University$11,389,307
- John Otridge · Leidos Biomedical Research, Inc.$8,845,576
- Sandhya Vasan · Henry M. Jackson Fdn For The Adv Mil/Med$7,776,394
Research focus
Combination ImmunotherapyCheckpoint InhibitionCharacteristicsChemotherapyBindingAnticancer ResearchAdvisory CommitteesBiological MarkersBiomarker DevelopmentBiomarker ValidationCancer CellCancer DiagnosisBioinformaticsCancer ImmunotherapyCareerCareer DevelopmentCd47 GeneCd8b1 GeneCdk4 GeneCell CommunicationCell CycleCell Cycle InhibitionCessation Of LifeCtla4 Gene
Grant awards (5)
Immunophenotypic biomarkers to predict response and optimize immunotherapy-based combinations in breast cancer$266,518
K08 · FY2023 · CA · contact PI
Immunophenotypic biomarkers to predict response and optimize immunotherapy-based combinations in breast cancer$266,518
K08 · FY2022 · CA · contact PI
Immunophenotypic biomarkers to predict response and optimize immunotherapy-based combinations in breast cancer$265,878
K08 · FY2021 · CA · contact PI
Immunophenotypic biomarkers to predict response and optimize immunotherapy-based combinations in breast cancer$265,878
K08 · FY2020 · CA · contact PI
Immunophenotypic biomarkers to predict response and optimize immunotherapy-based combinations in breast cancer$265,878
K08 · FY2019 · CA · contact PI